Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has conferred the title of Associate Professor to Yoel Lubell, Head of Economics and Translational Research at MORU, to Olivo Miotto from the Centre for Genomics and Global Health at MORU, and to Ronald Geskus from OUCRU. Louise Thwaites, Clinical Research Fellow at OUCRU, was appointed University Research Lecturer.

Oxford city skyline

The University of Oxford has conferred the title of Associate Professor to Yoel Lubell, Head of Economics and Translational Research, to Olivo Miotto from the Centre for Genomics and Global Health, and to Ronald Geskus from OUCRU. Louise Thwaites, Clinical Research Fellow at OUCRU, our sister unit in Vietnam, was appointed University Research Lecturer.

Based in MORU's Mathematical/Economic Modelling (MAEMOD) Department in Bangkok, Thailand, Professor Yoel Lubell leads the Economics and Translational Research Group (ETRG). ETRG focuses on the evaluation of diagnostics, treatments and vaccines for malaria and other infectious diseases. These evaluations are pursued using a variety of approaches ranging from economic and epidemiological modelling through laboratory investigations to clinical trials and qualitative research. Our ultimate aim is to provide policy makers with pragmatic and context specific assessments of the impact of new interventions if implemented in routine care. Where relevant we strive to take a broader view of the costs and benefits of new interventions accounting for factors such as their indirect impact on disease transmission and antimicrobial resistance as well as how such interventions’ cost-effectiveness varies in different epidemiological and socio-economic contexts or due to factors such as patents and health workers’ acceptance.

Professor Olivo Miotto focuses on translating the massive quantities of data produced by sequencing thousands of genomes into meaningful knowledge about the epidemiology of Plasmodium falciparum. By analyzing hundreds of thousands of genomic variations in each blood sample, he studies the genetics of parasite populations in four continents, and identifies patterns of evolution associated to responses to drug pressure and other human interventions. Based at MORU in Bangkok, Olivo collaborates with many clinical research groups in malaria endemic regions, particularly in Southeast Asia, to study relationships between  response to clinical therapy and genetics of the disease-causing parasites in the patient. In the early stages, the focus is on immediate problems, such as discovering mutations causing resistance to current drugs, such as artemisinin. However, Olivo's longer-term perspective is to create tools that will identify patterns in thousands of accumulated genomic sequences, leading to a deep understanding of parasite evolution and, ultimately, to interventions that will win the struggle against the disease.

Similar stories

New antibiotic combination speeds recovery from severe scrub typhus, which infects 1 million people per year

Treating patients ill with severe scrub typhus – a life-threatening infection that kills tens of thousands of people a year - with a combination of intravenous antibiotics doxycycline and azithromycin is significantly more effective than the current monotherapy of using either drug alone, say researchers in a study published in the New England Journal of Medicine (NEJM).

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Study supports evidence ivermectin not effective to treat COVID-19

21 Feb 2023 Oxford UK - High doses of the drug ivermectin, controversially recommended by some high-profile political and media figures during the COVID-19 pandemic, is ineffective at treating the COVID-19 virus, say University of Oxford-affiliated researchers in a study published today in eLife.

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

Ricardo Aguas awarded Associate Professorship

We are delighted to announce that Ricardo Aguas has been awarded the Associate Professor title, in recognition of his achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.

COPCOV investigators meet, and prepare to submit for publication

On 15-16 Dec, COPCOV investigators from around the world met in Bangkok to review study results and plan next steps. Led by co-PIs Prof Sir Nick White and Dr Will Schilling, and funded by the Wellcome Trust, the MORU-led COPCOV ( Chloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting) is the world’s largest multinational trial of COVID-19 prevention.